568.91
-41.95(-6.87%)
Currency In USD
| Previous Close | 610.86 |
| Open | 563.21 |
| Day High | 578.79 |
| Day Low | 542.85 |
| 52-Week High | 1,211.2 |
| 52-Week Low | 525.99 |
| Volume | 2.61M |
| Average Volume | 1.04M |
| Market Cap | 60.85B |
| PE | 14.47 |
| EPS | 39.31 |
| Moving Average 50 Days | 640.64 |
| Moving Average 200 Days | 846.89 |
| Change | -41.95 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,243.63 as of April 30, 2025 at a share price of $568.91. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $1,081.82 as of April 30, 2025 at a share price of $568.91.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
GlobeNewswire Inc.
Apr 28, 2025 11:01 AM GMT
Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patients who face cycles of relapse and remission TARR
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
GlobeNewswire Inc.
Apr 22, 2025 10:00 AM GMT
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region Regeneron’s ongoing and planned investments
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
GlobeNewswire Inc.
Apr 18, 2025 7:00 PM GMT
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics Lic